Glycostat will enable to maintain the blood glucose level within set limits by offering advice on the required insulin infusion rate
Flowsion has secured CE mark approval for its Glycostat automated glucose control system. (Credit: Jai79 from Pixabay)
Denmark-based medical device company Flowsion has secured CE mark approval for its Glycostat automated glucose control system for intensive care medicine.
Glycostat is claimed to be the only blood glucose control system to be rolled out in the European Union (EU) with an algorithm that facilitates automated blood glucose control for patients in intensive care.
Glycostat is an intravenous sensor specially designed for tight glycemic control (TGC) in the critical care market.
The system will help continuously measure, record and track the blood glucose level (BGL) in critically ill patients. It can also deliver appropriate alarms when hypo and hyperglycemic readings are required.
Glycostat system also helps in maintaining the blood glucose level within set limits by offering advice on the required insulin infusion rate.
Flowsion CEO Hans Jorgen Pedersen said: “With the CE mark we have reached an important milestone in our efforts to help patients and hospitals solving the important problem of glycemic control in the intensive care unit (ICU). For Flowsion this opens a globally relevant market opportunity.
“Flowsion has already performed clinical studies with the system so we know already that Glycostat fulfils the demands of the intensive care units.”
Flowsion has secured funding from the European Union’s Horizon 2020 research and innovation programme for the Glucostat project.
The company also noted that it has secured support from The EU SME programme, which helps internationally-oriented SMEs in implementing high-risk and high-potential innovation ideas.